Literature DB >> 3844465

Reduction of contact factors in sickle cell disease.

E M Gordon, B L Klein, B W Berman, S E Strandjord, J E Simon, P F Coccia.   

Abstract

Surface-mediated reactions of clotting were compared in 21 black children with homozygous sickle cell disease, 12 age-matched controls, and 15 adults. Both the coagulant and antigen titers of Hageman factor (factor XII) were decreased in asymptomatic patients compared with those in the control groups. These findings were associated with slight but significant reductions in the plasma titers of prekallikrein and high molecular weight kininogen. A further decrease from the initially low titers of these contact factors was observed during vaso-occlusive crises. Additionally, we observed a disparate relationship between Hageman factor coagulant activity and its antigen titers. These data provide evidence for reduction of the contact factors in patients with homozygous sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3844465     DOI: 10.1016/s0022-3476(85)80669-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Red blood cells and thrombin generation in sickle cell disease.

Authors:  Matthew F Whelihan; Ming Y Lim; Nigel S Key
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Malgorzata Kasztan; Michael W Henderson; Patrick Ellsworth; Parker Ross Davis; Kathryn J Wilson; Brandi Reeves; Nigel S Key; Sidney Strickland; Keith McCrae; David M Pollock; Rafal Pawlinski
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

Review 3.  Sickle cell disease: an inherited thrombophilia.

Authors:  Ted Wun; Ann Brunson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 5.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

Review 6.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

Review 7.  Therapeutic strategies for sickle cell disease: towards a multi-agent approach.

Authors:  Marilyn J Telen; Punam Malik; Gregory M Vercellotti
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

Review 8.  Linking Labile Heme with Thrombosis.

Authors:  Marie-Thérèse Hopp; Diana Imhof
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.